SCHEMBL3015000

SCHEMBL3015000

Cc1ccc(-c2csc(N3CCC(S(=O)(=O)c4cccc(Cl)c4)CC3)n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.53
RAB9A P51151 6/20 0.53
NPC1 O15118 5/20 0.53
MAPT P10636 6/20 0.51
CYP1A2 P05177 2/20 0.51
CYP2C9 P11712 2/20 0.51
CYP2C19 P33261 2/20 0.51
KMT2A Q03164 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
ALDH1A1 P00352 1/20 0.51
POLB P06746 1/20 0.51
HPGD P15428 1/20 0.51
HTT P42858 1/20 0.51
KDM1A O60341 2/20 0.44
MAPK1 P28482 4/20 0.44
LMNA P02545 3/20 0.44
MEN1 O00255 1/20 0.44
TSHR P16473 1/20 0.44
KCNQ1 P51787 1/20 0.43
MAOA P21397 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015722 0.93 SMN1; SMN2 (0.55) SMN1; SMN2RAB9ANPC1MAPTCYP1A2
SCHEMBL3013271 0.92 RAB9A (0.52) SMN1; SMN2RAB9ANPC1MAPTCYP1A2
SCHEMBL3018657 0.92 SMN1; SMN2 (0.57) SMN1; SMN2RAB9ANPC1MAPTCYP1A2
SCHEMBL3010126 0.91 SMN1; SMN2 (0.56) SMN1; SMN2RAB9ANPC1MAPTCYP1A2
SCHEMBL3015016 0.91 RAB9A (0.58) SMN1; SMN2RAB9ANPC1MAPTCYP1A2
SCHEMBL3013830 0.90 RAB9A (0.53) SMN1; SMN2RAB9ANPC1MAPTCYP1A2
SCHEMBL2999993 0.90 RAB9A (0.59) SMN1; SMN2RAB9ANPC1MAPTCYP1A2
SCHEMBL3013511 0.90 MAPT (0.56) SMN1; SMN2RAB9ANPC1MAPTKMT2A
SCHEMBL3009891 0.90 SMN1; SMN2 (0.50) SMN1; SMN2RAB9ANPC1MAPTCYP1A2
SCHEMBL3018530 0.88 SMN1; SMN2 (0.53) SMN1; SMN2RAB9ANPC1MAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.